Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.
Sponsor: Lynk Pharmaceuticals Co., Ltd
Summary
This is a randomized, double-blind study comparing LNK01001 to placebo in participants with moderately to severely atopic dermatitis who were candidates for systemic therapy (ie, patients with a history of inadequate response to topical treatments, those who were using a systemic treatment, or those for whom topical treatments are otherwise medically inadvisable). The objective of this study is to evaluate the efficacy and safety of LNK01001 in adult patients with moderate to severe AD who are candidates for systemic therapy.
Official title: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate LNK01001 in Adults Subjects With Moderate to Severe Atopic Dermatitis.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
354
Start Date
2024-02-06
Completion Date
2025-11-30
Last Updated
2025-06-27
Healthy Volunteers
No
Conditions
Interventions
LNK01001
Capsule; Oral
Placebo
Capsule; Oral
Locations (1)
Dermatological Hospital of Southern Medical University
Guangzhou, China